✦ LIBER ✦

Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma

✍ Scribed by Kensei Tobinai; Michinori Ogura; Yukio Kobayashi; Toshiki Uchida; Takashi Watanabe; Takashi Oyama; Dai Maruyama; Tatsuya Suzuki; Masakazu Mori; Masanobu Kasai; Damien Cronier; James E. Wooldridge; Minori Koshiji

Book ID: 108586958
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 286 KB
Volume: 102
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2010.01809.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of radioimmunotherapy with

Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma

✍ Takashi Watanabe; Shoji Terui; Kuniaki Itoh; Takashi Terauchi; Tadahiko Igarashi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Phase I/II study of humanized anti-CD33

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

✍ Yukio Kobayashi; Kensei Tobinai; Akihiro Takeshita; Kensuke Naito; Osamu Asai; N 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 231 KB

Phase II study of a TLR-9 agonist (1018

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

✍ Jonathan W. Friedberg; Jennifer L. Kelly; Donna Neuberg; Derick R. Peterson; Jef 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB